Subjects were assigned randomly to groups given simeprevir ( 150 mg/day ) and sofosbuvir ( 400 mg/day ) ( n = 58 in the final analysis ) or peginterferon alfa 2b ( 1.5 mcg/kg/wk ) , ribavirin ( 1000-1200 mg/day ) , and sofosbuvir ( 400 mg/day ) ( n = 24 in the final analysis ) .